Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences

Pasithea Therapeutics (KTTA) will participate in two investor conferences in September 2026 to engage with investors and present its business.

Rhea-AI Summary

Pasithea Therapeutics (KTTA) will participate in two investor conferences in September 2026 to engage with investors and present its business.

Management will hold one-on-one meetings at the 12th Annual Cantor Global Healthcare Conference in New York, NY, from September 9-11, 2026. Management will also present at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026, with the company’s presentation scheduled for Monday, September 14, 2026, at 2:30 PM ET. Pasithea is a clinical-stage biotech developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for chronic diseases including neurocutaneous manifestations of NF1.

Argus Sep 4 session

-0.07% close to close Open Argus

Details

News Market Reaction – KTTA

On Sep 4, the first trading day after this news, KTTA closed 0.07% below the previous close.

Data tracked by StockTitan Argus for the Sep 4 session.

Key Figures

Investor conferences: 2 conferences Cantor conference: 12th Annual Cantor conference dates: September 9-11, 2026 +3 more

Investor conferences

2 conferences

September 2026

Cantor conference

12th Annual

Cantor Global Healthcare Conference

Cantor conference dates

September 9-11, 2026

New York, NY

H.C. Wainwright conference

28th Annual

Global Investment Conference

Wainwright conference dates

September 14-16, 2026

Company presentation scheduled during conference

Presentation time

2:30 PM ET

Monday, September 14, 2026

Historical Context

5 past events · Latest: Jul 21

5 events

1. Jul 21

   ESMO data presentation

   24h Move

   -3.9%

   Scheduled presentation of Phase 1 PAS-004 dose-escalation data at ESMO

2. Jul 08

   Investor conference participation

   24h Move

   -1.6%

   One-on-one meetings and discussions scheduled at B. Riley summit

3. Jun 30

   Phase 1 clinical data

   24h Move

   -2.0%

   Interim data showed safety, durable stabilization, and chronic-dosing pharmacokinetics

4. Jun 16

   Clinical protocol amendment

   24h Move

   -8.9%

   Protocol added higher doses, longer treatment, and expanded imaging assessments

5. Jun 15

   Conference exhibition

   24h Move

   -5.3%

   Company scheduled exhibition at the 2026 NF Conference

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

macrocyclic, MEK inhibitor, neurofibromatosis type 1

3 terms

macrocyclic technical

"a next-generation macrocyclic oral MEK inhibitor"

A macrocyclic is a large, ring-shaped molecule used in drugs and other products; imagine a tiny chemical bracelet where the ends are joined to form a loop. Its ring structure often gives unusual stability, the ability to bind targets precisely, and distinct behavior in the body compared with smaller molecules. For investors, macrocyclics can signal potential for novel therapies, stronger patent protection, and often higher development or manufacturing complexity and cost.

MEK inhibitor medical

"a next-generation macrocyclic oral MEK inhibitor"

A MEK inhibitor is a drug that blocks MEK enzymes, which act like a relay in a cell’s growth-signaling pathway; by cutting that relay these drugs can slow or stop uncontrolled cell growth seen in some cancers and other proliferative conditions. Investors care because clinical trial outcomes, safety data, and regulatory approvals determine whether a MEK inhibitor becomes a marketable therapy, directly affecting a developer’s revenue prospects and valuation — like a product passing a crucial safety and sales test.

neurofibromatosis type 1 medical

"neurocutaneous manifestations of neurofibromatosis type 1 (NF1)"

A genetic condition that causes noncancerous tumors to grow on nerves and can lead to skin changes, pain, learning challenges and other complications; severity varies widely from mild to serious. Investors track it because treatments, diagnostics and care pathways for this distinct patient group can drive clinical trial outcomes, regulatory approvals and long‑term revenue, much like a niche market where the size, unmet need and treatment complexity determine potential returns.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

-- Company will hold one-on-one investor meetings at the 12th Annual Cantor Global Healthcare Conference (September 9-11) and will present at the H.C. Wainwright 28th Annual Global Investment Conference (September 14-16) --

MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced that management will participate in two investor conferences taking place in September 2026: the 12th Annual Cantor Global Healthcare Conference, hosted by Cantor Fitzgerald, and the H.C. Wainwright 28th Annual Global Investment Conference.

12th Annual Cantor Global Healthcare Conference

Management will hold one-on-one investor meetings at the 12th Annual Cantor Global Healthcare Conference, taking place September 9-11, 2026, in New York, NY. 

H.C. Wainwright 28th Annual Global Investment Conference

Management will also present at the H.C. Wainwright 28th Annual Global Investment Conference, being held September 14-16, 2026, with the Company's presentation scheduled for Monday, September 14, 2026, at 2:30 PM ET.

About Pasithea Therapeutics Corp.

Pasithea is a clinical-stage biotechnology company primarily focused on the research and development of its lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor intended for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The Company is currently testing PAS-004 in a Phase 1 clinical trial in advanced cancer patients (NCT06299839), and a Phase 1/1b clinical trial in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NCT06961565).

Forward Looking Statements

This press release contains statements that constitute "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the Company’s ongoing Phase 1 clinical trial of PAS-004 in advanced cancer patients, the Company’s Phase 1/1b clinical trial of PAS-004 in adult NF1 patients, and the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and preliminary efficacy of PAS-004, as well as all other statements, other than statements of historical fact, regarding the Company’s current views and assumptions with respect to future events regarding its business, as well as other statements with respect to the Company’s plans, assumptions, expectations, beliefs and objectives, the success of the Company’s current and future business strategies, product development, pre-clinical and non-clinical studies, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth and financing opportunities and other statements that are predictive in nature. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including risks that future clinical trial results may not match results observed to date, may be negative or ambiguous, or may not reach the level of statistical significance required for regulatory approval, as well as other factors set forth in the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and other filings made with the U.S. Securities and Exchange Commission (SEC). Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.

Contact

Patrick Gaynes
Investor Relations
pgaynes@pasithea.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What investor conferences will Pasithea Therapeutics (KTTA) attend in September 2026?

Pasithea Therapeutics will participate in the 12th Annual Cantor Global Healthcare Conference and the H.C. Wainwright 28th Annual Global Investment Conference, both taking place in September 2026.

When and where is Pasithea Therapeutics (KTTA) meeting investors at the Cantor Global Healthcare Conference?

Management will hold one-on-one investor meetings at the 12th Annual Cantor Global Healthcare Conference in New York, NY, from September 9-11, 2026.

When is Pasithea Therapeutics’ presentation at the H.C. Wainwright Global Investment Conference for KTTA?

At the H.C. Wainwright 28th Annual Global Investment Conference, Pasithea Therapeutics’ presentation is scheduled for Monday, September 14, 2026, at 2:30 PM ET, during the event being held from September 14-16, 2026.

What type of company is Pasithea Therapeutics (KTTA) and what is PAS-004?

Pasithea Therapeutics is a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor intended for long-term treatment of chronic diseases, including neurocutaneous manifestations of neurofibromatosis type 1 (NF1).